Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non–Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases

Background: Zoledronic acid every 4 weeks (Q4wk) reduces the incidence of skeletal-related events (SREs) in patients with metastatic lung cancer. Lung cancer patients were excluded from extended-interval dosing trials (every 12 weeks [Q12wk]) that demonstrated noninferiority of the 2 dosing schemes....

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The Annals of pharmacotherapy 2021-06, Vol.55 (6), p.697-704
Hauptverfasser:	Tam, Andrew H., Schepers, Allison J., Qin, Angel, Nachar, Victoria R.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!